| NASDAQ (usa) |
|
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
| DAX (german) |
|
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Atossa Therapeutics Inc (STU: YAG2)
YAG2 Technical Analysis
5
| As on 16th Dec 2025 YAG2 STOCK Price closed @ 0.60 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.76 & Strong Sell for SHORT-TERM with Stoploss of 0.92 we also expect STOCK to react on Following IMPORTANT LEVELS. |
YAG2STOCK Price
| Open | 0.60 | Change | Price | % |
| High | 0.60 | 1 Day | -0.06 | -9.09 |
| Low | 0.60 | 1 Week | -0.08 | -11.76 |
| Close | 0.60 | 1 Month | -0.13 | -17.81 |
| Volume | N/A | 1 Year | -0.60 | -50.00 |
| 52 Week High 1.20 | 52 Week Low 0.52 | ||||
STU Germany Most Active Stocks
| 9AJ1 | 0.02 | -33.33% |
| 9AJ1 | 0.02 | -33.33% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| TINC | 0.01 | -1.50% |
| PGF | 19.13 | -90.20% |
| PGF | 19.13 | -90.20% |
STU Germany Top Gainers Stocks
STU Germany Top Losers Stocks
| YAG2 Daily Charts |
YAG2 Intraday Charts |
Whats New @ Bazaartrend |
YAG2 Free Analysis |
|
|
YAG2 Important Levels Intraday
| RESISTANCE | 0.60 |
| RESISTANCE | 0.60 |
| RESISTANCE | 0.60 |
| RESISTANCE | 0.60 |
| RESISTANCE | 0.60 |
| RESISTANCE | 0.60 |
| RESISTANCE | 0.60 |
| RESISTANCE | 0.60 |
YAG2 Forecast December 2025
| 4th UP Forecast | 1.12 |
| 3rd UP Forecast | 0.95 |
| 2nd UP Forecast | 0.85 |
| 1st UP Forecast | 0.75 |
| 1st DOWN Forecast | 0.45 |
| 2nd DOWN Forecast | 0.35 |
| 3rd DOWN Forecast | 0.25 |
| 4th DOWN Forecast | 0.08 |
YAG2 Weekly Forecast
| 4th UP Forecast | 0.83 |
| 3rd UP Forecast | 0.76 |
| 2nd UP Forecast | 0.71 |
| 1st UP Forecast | 0.67 |
| 1st DOWN Forecast | 0.53 |
| 2nd DOWN Forecast | 0.49 |
| 3rd DOWN Forecast | 0.44 |
| 4th DOWN Forecast | 0.37 |
YAG2 Forecast2025
| 4th UP Forecast | 1.95 |
| 3rd UP Forecast | 1.52 |
| 2nd UP Forecast | 1.25 |
| 1st UP Forecast | 0.98 |
| 1st DOWN Forecast | 0.22 |
| 2nd DOWN Forecast | -0.05 |
| 3rd DOWN Forecast | -0.32 |
| 4th DOWN Forecast | -0.75 |
Atossa Therapeutics Inc ( STU Germany Symbol : YAG2 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
YAG2 Other Details
| Segment | EQ | |
| Market Capital | 286982080.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
YAG2 Address
![]() |
||
YAG2 Latest News
YAG2 Business Profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

